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Summary
The endogenous lipid signaling agent oleoylethanolamide (OEA) has recently been described as a peripherally acting agent
that reduces food intake and body weight gain in rat feeding models. This paper presents evidence that OEA is an endog-
enous ligand of the orphan receptor GPR119, a G protein-coupled receptor (GPCR) expressed predominantly in the human
and rodent pancreas and gastrointestinal tract and also in rodent brain, suggesting that the reported effects of OEA on food
intake may be mediated, at least in part, via the GPR119 receptor. Furthermore, we have used the recombinant receptor to
discover novel selective small-molecule GPR119 agonists, typified by PSN632408, which suppress food intake in rats and
reduce body weight gain and white adipose tissue deposition upon subchronic oral administration to high-fat-fed rats.
GPR119 therefore represents a novel and attractive potential target for the therapy of obesity and related metabolic disor-
ders.Introduction
The rapidly increasing prevalence of obesity in Westernized so-
cieties and in some developing countries has focused the efforts
of healthcare providers and pharmaceutical companies on the
search for new, efficacious, and safe treatments to counter
this problem (Jandacek and Woods, 2004; Stein and Colditz,
2004). We are engaged in the search for agents that alter various
physiological signaling systems, either through attenuating hun-
ger signals or through eliciting premature satiety following meal
ingestion, and that may act as novel anti-obesity therapies.
Recently, a number of fatty acids have been shown to act as
ligands at G protein-coupled receptors (GPCRs) (Briscoe et al.,
2003; Itoh et al., 2003; Hirasawa et al., 2004), and fatty-acid de-
rivatives including anandamide (arachidonylethanolamide; AEA)
and 2-arachidonyl glycerol may be endogenous ligands at the
cannabinoid receptors CB1 and CB2 (Devane et al., 1992; Ha-
nus et al., 1993; Mechoulam et al., 1995; Sugiura et al., 1995).
Recent publications have demonstrated that the orphan recep-
tor GPR55 responds to a similar series of fatty-acid ethanola-
mides and related compounds as do the cannabinoid receptors
(A.J. Brown et al., 2005, Symposium on the Cannabinoids, Bur-
lington, Vermont, International Cannabinoid Research Society,
p. 16; S. Sjogren et al., 2005, p.106). This includes ‘‘standard’’
endogenous and synthetic cannabinoids as well as lipids with
shorter chains/higher saturation such as palmitoylethanolamide
(PEA). Due to this overlap of endogenous activating ligands, the
adoption of the CB3 nomenclature for GPR55 may follow in due
course. Although it is tempting to speculate that GPR35, whichCELL METABOLISM 3, 167–175, MARCH 2006 ª2006 ELSEVIER INC.by clustering analysis is the closest relation to GPR55 (Fredriks-
son et al., 2003), may also be ultimately identified as a ‘‘cannabi-
noid’’ receptor, this presently remains to be established.
The CB1 receptor is known to play a role in food intake in rats
and humans, and its modulation by antagonists such as rimona-
bant (SR-141716) is a promising approach for the control of obe-
sity (Cota et al., 2003; Black, 2004). The endogenous fatty-acid
ethanolamide oleoylethanolamide (OEA) has recently been de-
scribed as a peripherally acting agent that suppresses food in-
take and, upon subchronic intraperitoneal administration, re-
duces body weight gain in rodent feeding models (Rodriguez
de Fonseca et al., 2001; Fu et al., 2003; Gaetani et al., 2003;
Oveisi et al., 2004; Nielsen et al., 2004; Piomelli et al., 2004).
This present work provides evidence that OEA is an agonist at
GPR119 (Fredriksson et al., 2003), an orphan GPCR expressed
predominantly in the pancreas and gastrointestinal tract in hu-
mans and in the brain, pancreas, and gastrointestinal tract in ro-
dents (Bonini et al., 2002).
In view of the gastrointestinal localization of GPR119, we hy-
pothesized that the reported effects of OEA on feeding may be
mediated, at least in part, by this receptor and that nonlipidic
GPR119 agonists would therefore provide a novel means of
pharmaceutical intervention to reduce food intake. We therefore
expressed recombinant human and mouse GPR119 in a yeast
assay system and used this to screen a proprietary small-mole-
cule library of several hundred thousand compounds for novel
agonists. An optimized agonist, PSN632408, was then used to
test our hypothesis, and we report on the hypophagic effects
of this molecule in rat models of obesity.DOI 10.1016/j.cmet.2006.02.004 167
A R T I C L EResults and Discussion
Deorphanization of GPR119
In the course of our functional genomics program focused on or-
phan human GPCRs, one of the novel receptors identified was
designated OSGPR116. Subsequently, receptors designated
SNORF25 (Bonini et al., 2002) and GPR119 (Fredriksson et al.,
2003) were described in the literature, and their sequences
found to be identical to that of OSGPR116. The mRNA expres-
sion profile of OSGPR116 was similar to that described for
SNORF25 (data not shown). For the sake of clarity, the receptor
OSGPR116 is referred to as GPR119 in this paper.
Human and mouse isoforms of the receptor were cloned and
expressed in a yeast-based functional assay (described in Ex-
perimental Procedures) and a search for endogenous ligands
initiated. Since our homology clustering analysis had indicated
that the closest relatives of this GPCR are the cannabinoid re-
ceptors, a number of cannabinoid ligands and fatty-acid etha-
nolamides were tested as potential agonists. The endogenous
cannabinoid 2-arachidonyl glycerol and the synthetic cannabi-
noid ligands CP55940, WIN55212-2, methanandamide, and
JWH-133 did not activate the receptor in the yeast-based assay
(data not shown), while the endogenous cannabinoid arachido-
nylethanolamide (anandamide, AEA, C20:4, i.e., fatty-acid
chain length of 20 carbons with 4 double bonds) produced
a modest (2- to 3-fold) increase in fluorescence. In contrast,
the more saturated fatty-acid ethanolamides oleoylethanola-
Figure 1. Structures of OEA, PSN375963, and PSN632408168mide (OEA, C18:1, Figure 1), stearoylethanolamide (SEA,
C18:0), and palmitoylethanolamide (PEA, C16:0) produced
much greater increases in fluorescence (Figure 2), indicating
that these are agonists at this receptor. The rank order of effi-
cacy of these fatty-acid ethanolamides was identical at the hu-
man andmouse isoformswith OEA being themost efficacious in
each case. No response to OEA was observed in an equivalent
yeast strain in which the transforming plasmid lacked the
GPR119 gene (data not shown), demonstrating that the OEA ex-
erts its effect via the GPR119 receptor and not at some down-
stream point in the yeast signaling cascade. Linolenoyl ethano-
lamide (C18:3), linoleoyl ethanolamide (C18:2), and oleamide
(the primary amide of oleic acid) also activated the human and
mouse GPR119 receptors but with lower efficacies than OEA
(data not shown).
Recently, oleoyl lysophosphatidylcholine (18:1-LPC) has
been reported to be themost potent of a group of phospholipids
acting as agonists at GPR119 (Soga et al., 2005). 18:1-LPC was
tested in our yeast fluorimetric assay for human GPR119 and
confirmed to be an agonist, although with a substantially lower
activity than OEA (EC50 > 30 mM, compared to 3.2 mM for
Figure 2. Fatty-acid ethanolamides are agonists at GPR119
Fold induction of signal (means; n = 4) by fatty-acid ethanolamides in yeast fluori-
metric assay for (A) human GPR119 and (B) mouse GPR119.
OEA—filled triangles; PEA—open triangles; SEA—filled squares; AEA—open dia-
monds (see text for definitions).CELL METABOLISM : MARCH 2006
A GPCR for OEA and synthetic hypophagic agentsOEA; 11-fold induction of signal with 100 mM 18:1-LPC com-
pared to 30-fold with 100 mM OEA).
OEA, PEA, and SEA have all been described as agents capa-
ble of reducing food intake in rodent models (Rodriguez de Fon-
seca et al., 2001; Terrazzino et al., 2004). The discovery that
these molecules act as agonists of an intestinally localized
GPCR led us to hypothesize that GPR119 plays a role in the me-
diation of this hypophagic effect, and that small-molecule ago-
nists could thus provide a novel means of pharmaceutical inter-
vention to reduce food intake.
The identification of CB1 and CB2 (Matsuda et al., 1990;
Munro et al., 1993) as two rather dissimilar receptors (about
44% amino acid homology) activated by a similar series of en-
dogenous lipids demonstrated the existence of a subfamily of
GPCRs now termed ‘‘cannabinoid receptors.’’ Although addi-
tional cannabinoid receptors have been postulated and demon-
strated to exist, either pharmacologically or through the use of
CB1/CB2 receptor knockout mice (for example, Ja´rai et al.,
1999; Breivogel et al., 2001), the molecular identification of fur-
ther cannabinoid receptors has not been forthcoming. The vanil-
loid receptor TRPV1, an ion channel, has been shown to be ac-
tivated by anandamide (Zygmunt et al., 1999), but this receptor
alone cannot account for all the non-CB1, non-CB2 receptor
pharmacology described in the literature. GPR55 has recently
been demonstrated to respond to fatty-acid ethanolamides, as
described in the Introduction. Our identification of GPR119 as
another receptor that responds to the same family of ligands (al-
beit preferentially activated by shorter chain fatty-acid ethanola-
mides such as OEA and PEA, and positively coupled to adenyl-
ate cyclase in contrast to CB1 and CB2) further suggests that
the family of cannabinoid receptors is in fact significantly more
extensive than the long-accepted CB1/CB2 receptor pairing.
Identification of small-molecule GPR119 agonists
The yeast-based fluorimetric assay was used to conduct a high-
throughput screening campaign, leading to the identification of
a number of small-molecule GPR119 agonists. One of the com-
pounds identified, PSN375963 (Figure 1), showed similar po-
tency to OEA at both the mouse and human GPR119 receptors,
although its efficacy was lower (Table 1). Preliminary optimiza-
tion of PSN375963 yielded PSN632408 (Figure 1; Fyfe et al.,
2005), a compound similar in efficacy and potency to OEA at
both human and mouse GPR119 receptors (Table 1) but without
the lipophilicity associated with poor drug properties (Wenlock
et al., 2003) that is present in both OEA and PSN375963.
GPR119 agonists increase intracellular cAMP
A stable HEK 293-derived cell line (HEK-OSGPR116) that ex-
presses human GPR119 in a tetracycline-inducible manner
was generated. Quantitative RT-PCR was used to demonstrate
Table 1. GPR119 agonism in yeast fluorimetric assay
Human GPR119 Mouse GPR119
Emaxa,b EC50, mM
b Emaxa,b EC50, mM
b
OEA 1 3.2 6 0.33 1 2.9 6 0.59
PSN375963 0.29 6 0.03 8.4 6 2.7 0.53 6 0.04 7.9 6 2.4
PSN632408 1.1 6 0.04 5.6 6 0.99 1.1 6 0.03 7.9 6 0.7
aMaximal fold induction of signal normalized to value for OEA.
b Values are means 6 SEM.CELL METABOLISM : MARCH 2006a concentration-dependent increase in the expression of
GPR119 mRNA of two orders of magnitude when these cells
were treated with tetracycline as described in Experimental Pro-
cedures (Figure 3A).
The HEK-OSGPR116 cell line was used to investigate the ef-
fect of GPR119 agonists on intracellular levels of cyclic AMP
(cAMP). Treatment with either OEA or PSN632408 produced
concentration-dependent increases in cAMP level with mean
EC50 values of 2.9 6 0.46 mM for OEA and 1.9 6 0.14 mM for
PSN632408. Dose-response curves for a typical experiment
are shown in Figure 3B. When an equivalent experiment was
performed using control cells engineered to express chloram-
phenicol acetyl transferase instead of GPR119, neither OEA
nor PSN632408 produced any effect on the level of intracellular
cAMP (data not shown). These results demonstrate that ago-
nists at GPR119 stimulate adenylate cyclase, most likely by sig-
naling via Gas coupling.
PSN632408 is a selective agonist at GPR119
PSN632408 was tested for agonist activity at the human canna-
binoid receptors CB1 and CB2 using yeast-based reporter as-
says analogous to those developed for GPR119. No activation
was seen at concentrations up to 100 mM (data not shown).
Figure 3. GPR119 agonists stimulate adenylate cyclase in mammalian cells
A) Quantitative RT-PCR analysis of hGPR119-specific mRNA levels in HEK-
OSGPR116 cells treated with increasing concentrations of tetracycline.
B) Responses of intracellular cAMP levels to treatment of tetracycline-induced
HEK-OSGPR116 cells with OEA (filled circles) or PSN632408 (open squares). Re-
sults expressed as means 6 SEM.169
A R T I C L EFigure 4. Acute dosing of rats with GPR119 agonists
A) Cumulative food intake (g/kg body weight) in weight-matched groups of 8 or 9 male Sprague-Dawley rats (weight range 352–425 g) after i.p. administration of vehicle,
OEA (30 mg/kg), and PSN632408 (100 mg/kg). Results are expressed as means + SEM. Significant differences from the vehicle-treated controls are denoted by **p < 0.01
(one-way ANOVA followed by Dunnett’s multiple comparison test).
B)Cumulative food intake (g/kg body weight) and (C) locomotor activity (cumulative consecutive beam breaks) in weight-matched groups of 10 or 11male Sprague-Dawley
rats (weight range 293–339 g) after i.p. administration of vehicle (open squares) or PSN632408 at 10 mg/kg (filled triangles) or 30 mg/kg (filled diamonds). Data are ex-
pressed as means + SEM. Significant differences from the vehicle-treated controls are denoted by *p < 0.05 (ANOVA followed by Fisher’s post-hoc test).Activation of human PPARg was tested in a stable HT-29-de-
rived reporter cell line. No activation was obtained upon treat-
ment with PSN632408 at concentrations up to 10 mM (Fig-
ure S1A available with this article online).
The ability of PSN632408 to activate rat and human PPARa
was assayed at Exygen Research (Penn State University, PA)
using 3T3-derived stable reporter cell lines. No activation of
rat PPARawas seen at concentrations up to 30 mM (Figure S1B).
Similar results were obtained for human PPARa (data not
shown).
The selectivity of PSN632408 was further evaluated at 10 mM
against a set of 107 targets comprising GPCRs (61), ligand-
gated ion channels (7), other receptors (5), ion channels (9),
amine transporters (5), and enzymes (16) at Cerep (Celle L’Eves-
cault, France) and MDS Pharma Services (Taipei, Taiwan).
Included in the analysis were the following feeding-related re-
ceptors: cannabinoid CB1, cholecystokinin, ghrelin, leptin, glu-170cagon-like peptide-1, 5-hydroxytryptamine, melanin concen-
trating hormone-1, melanocortin-4, and histamine-H3. At none
of the 107 targets was inhibition greater than 30% observed.
In addition, no binding was detectable at the rat TRPV1 recep-
tor, which is activated by anandamide and which may also me-
diate some OEA effects (Zygmunt et al., 1999; Wang et al.,
2005). PSN632408 was also tested in the hERG K+ channel ru-
bidium ion efflux assay (Cerep, Celle L’Evescault, France) and
did not show any inhibition at 10 mM.
OEA and PSN632408 acutely reduce food intake in rats
The acute effects of GPR119 agonists on food intake were in-
vestigated using a rat feedingmodel as described in Experimen-
tal Procedures. Figure 4A shows the effects of intraperitoneal
(i.p.) administration of OEA (30 mg/kg) and PSN632408
(100 mg/kg) on cumulative food intake in freely feeding male
Sprague-Dawley rats. Both agents produced a reduction inCELL METABOLISM : MARCH 2006
A GPCR for OEA and synthetic hypophagic agentsfood intake. In the case of OEA, this reduction was statistically
significant at 1 hr and 2 hr post-dosing only, although food in-
take remained lower than for the control group at later time
points, giving a profile similar to that reported by Gaetani et al.
(2003) and Proulx et al. (2005) using a 20 mg/kg intraperitoneal
dose of OEA. In contrast, the cumulative food intake of animals
dosed with PSN632408 remained significantly lower than the
vehicle-treated group at all time points up to 24 hr. No overt ad-
verse behavioral effects were observed with either compound.
The hypophagic effect of PSN632408 is independent of stom-
ach content since equivalent reductions in food intake were
seen upon dosing with PSN632408 (100 mg/kg i.p.) in freely
feeding and 18 hr fasted rats (Figure S2).
The effects of lower doses of PSN632408 (10 and 30 mg/kg
i.p.) were then investigated using an automated system provid-
ing continuous concurrent measurements of food intake and lo-
comotor activity. Hourly cumulative totals for these parameters
have been plotted in Figures 4B and 4C. There was a slight
trend, albeit not statistically significant, toward lower cumulative
food intake at the 10 mg/kg dose, while the 30 mg/kg dose pro-
duced a statistically significant reduction at all time points from 3
to 17 hr post-dosing (Figure 4B). No rebound in food intake oc-
curred: food intake in the PSN632408-treated rats showed no
statistically significant difference from vehicle-treated controls
in the 24–48 hr period (vehicle = 81.1 6 4.9 g/kg body weight;
10 mg/kg PSN632408 = 83.1 6 4.6 g/kg body weight; 30 mg/
kg PSN632408 = 82.9 6 3.2 g/kg body weight). Administration
of PSN632408 did not significantly alter locomotor activity
(Figure 4C), suggesting that the observed decrease in food in-
take induced by the 30 mg/kg dose was not simply due to non-
specific behavioral depression (or hyperactivity). It has been re-
ported that a hypophagic dose of OEA (20 mg/kg i.p.) causes
a statistically significant reduction in locomotor activity (Rodri-
guez de Fonseca et al., 2001; Proulx et al., 2005) and that the
effect may be modulated by activation of TRPV1 by OEA
(Wang et al., 2005; Proulx et al., 2005). Under the conditions
of our experiment, we did not note any effect by PSN 632408
on locomotor activity, possibly because of its greater selectivity
for GPR119 compared to OEA.
The possibility that the hypophagic response to PSN632408
may be due to the production of aversive signals was investi-
gated by a conditioned taste aversion study (CTA; Tang-Chris-
tensen et al., 1998) in rats dosed intraperitoneally with a hypo-
phagic dose (30 mg/kg) of PSN632408. No induction of CTA,
as assessed by saccharin preference ratio, was produced
(Figure S3A). Additionally, PSN632408 (30 mg/kg i.p.) did not in-
crease kaolin intake over control levels in a kaolin consumption
study (Figure S3B), hence there is no evidence of drug-induced
malaise (Madden et al., 1999). The effects of this compound on
food intake are therefore unlikely to be a result of nonspecific
toxicity.
OEA has previously been reported to activate PPARa (Fu
et al., 2003) and TRPV1 (Wang et al., 2005). Fu et al. (2003)
have presented evidence that PPARa null mice are not suscep-
tible to the effects of OEA (dosed intraperitoneally) upon food in-
take and body weight that are seen in their lean littermates, im-
plicating PPARa as OEA’s principal target. OEA was shown to
alter expression of several PPARa target genes in the jejunum
of wild-type but not PPARa null mice, including a repression of
the inducible nitric oxide synthase gene, and it was proposed
that the resulting reduction in nitric oxide could lead to stimula-CELL METABOLISM : MARCH 2006tion of vagal afferents (Fu et al., 2003). A transcriptionally regu-
lated effect such as this would be expected to have a slow onset
and persist over several hours. Wang et al. (2005) have demon-
strated that short-term food intake is reduced in response to
OEA in wild-type but not TRPV1 null mice and postulate that
TRPV1 is an additional target for OEA, mediating an immediate
suppression of feeding via direct excitation of vagal sensory
neurons.We have found that OEA also acts as an agonist at gas-
tro-intestinally expressed GPR119, suggesting a third possible
mechanism by which its hypophagic effects might be mediated.
The relative contributions of these three potential targets to the
hypophagic action of OEA is still to be determined.
PSN632408, a selective GPR119 agonist, does not bind to the
TRPV1 receptor (or to a panel of other feeding-related receptors)
and does not activate PPARa using a functional assay (see
above). The hypophagia produced by PSN632408 is therefore
most probably due to activation of the GPR119 receptor.
PSN632408 also produced acute hypophagic effects when
dosed orally (Figure S4). At a dose of 100 mg/kg, food intake
was significantly reduced compared to control from 4 hr post-
dosing onward—total food intake over the first 24 hr post-dos-
ing was 10.4% lower in animals treated with 100 mg/kg
PSN632408 than in vehicle-treated controls (p < 0.05; ANOVA
followed by Fisher’s post-hoc test). A dose of 50 mg/kg
PSN632408 also produced a reduction in food intake, and 24
hr food intake was 3.6% lower than the vehicle control, but
this difference was not statistically significant. An oral dose of
100mg/kgwas therefore used for the subchronic dosing studies
described below.
Effects of chronic administration of PSN632408
Diet-induced obese (DIO) rats, which have become chronically
obese through access to high-energy, highly palatable food,
represent models with similarities to the human obesity state.
It was therefore of interest to determine whether a GPR119 ag-
onist could modulate food intake and body weight in such ani-
mals.
PSN632408 (100 mg/kg orally) was administered daily for 14
days to male rats with a genetic predisposition to obesity (Levin
et al., 1997; Levin and Keesey, 1998) fed with high-fat diet (HFD)
for 13 weeks prior to start of dosing and throughout the experi-
ment. Cumulative food intake was significantly lower in
PSN632408-treated animals than in vehicle controls throughout
the course of the experiment (Figure 5A). The mean daily food
intake was decreased by 10% during the first week of dosing
(controls = 21.05 6 0.30 g versus PSN632408 = 18.89 6 0.35
g; p < 0.02, Student’s two-sample t test) and 15% during the
second week (controls = 20.46 6 0.37 g versus PSN632408 =
17.29 6 0.29 g; p < 0.01, Student’s two-sample t test). Body
weight gain was significantly attenuated from day 6 onward
with some evidence of weight loss (Figure 5B). Over the course
of this short study, the vehicle-treated controls gained an aver-
age of 18.3 6 3.3 g, while PSN632408-treated animals lost an
average of 4.66 3.4 g. (Mean initial body weights for the groups
of animals are given in the legend to Figure 5.)
At the end of the experiment, body white adipose tissue de-
posits (mesenteric, retroperitoneal, epididymal, and subcutane-
ous inguinal fat) and intrascapular brown adipose tissue (IBAT)
depots were removed and weighed. All of the white adipose tis-
sue depots examined showed some reduction in mean weight
in the PSN632408-treated rats compared to vehicle-treated171
A R T I C L EFigure 5. Subchronic dosing of DIO rats with PSN632408
A)Cumulative food intake (g/kg body weight) and (B) body weight (percentage of day 0 value) for groups of 9 or 10 rats dosed daily p.o. (commencing on day 0) with vehicle
(open squares; mean body weight 545 6 17 g on day 0) or with 100 mg/kg PSN632408 (filled circles; mean body weight 551 6 14 g on day 0). Results are presented as
means + SEM. Significant differences from the vehicle-treated controls are denoted by *p < 0.05 (ANOVA followed by Fisher’s post-hoc test).
C)Weights of fat pad masses removed at day 14 (24 hr after last dose) from rats treated with vehicle (open bars) or PSN632408 (shaded bars). ING = inguinal, EP = ep-
ididymal, MES = mesenteric, RP = retroperitoneal, IBAT = intrascapular brown adipose tissue. Values expressed in g (mean + SEM). Significant differences from the ve-
hicle-treated controls are denoted by *p < 0.05 (ANOVA factorial, Fisher’s post-hoc test).animals; this effect reached statistical significance in the case
of the mesenteric fat depot. There was no effect on IBAT (Fig-
ure 5C).
A second subchronic study was conducted to examine the ef-
fects of PSN632408 using a different experimental paradigm, in
which normal male Sprague-Dawley rats in the active growing
phase are given a high-fat diet (see Experimental Procedures)
for 10 days prior to dosing and throughout the experiment (Fig-
ure 6). Animals were dosed orally for 24 days with vehicle,
PSN632408 (100 mg/kg), or sibutramine (5 mg/kg sibutramine
hydrochloride hydrate), a prescribed weight-loss agent (Heal
et al., 1998). For comparison, a fourth group was maintained
on standard chow and dosed with vehicle. Figure 6A shows cu-
mulative food intake over the course of the experiment—this is
expressed as kJ/kg body weight to allow for the differences in
diets. Cumulative food intake was significantly lower in
PSN632408-treated animals than in vehicle controls from day
5 onward and in sibutramine-treated animals from day 2 onward
(Figure 6A). Body weight gain was significantly reduced from
day 3 onward in PSN632408-treated animals and from day 1 on-
ward in sibutramine-treated animals (Figure 6B). During the first
days of dosing, body weight gain in the sibutramine-treated
group was markedly slower than in the PSN632408-treated an-172imals. During the latter part of the study, however, the two
groups gained weight at similar rates and by day 23 both groups
had increased in body weight by the same proportion as chow-
fed controls (131% 6 1.3% of starting weight for PSN632408,
132% 6 1.9% for sibutramine, and 131% 6 3.8% for chow-
fed controls compared to 142% 6 2.2% for the high-fat diet-
fed control group). This represents an overall weight gain of
102.9 6 5.0 g for PSN632408 treatment and 104.2 6 7.0 g for
sibutramine treatment, compared to 135.6 6 8.6 g for HFD-
fed controls. (Mean initial bodyweights for the groups of animals
are given in the legend to Figure 6.)
Analysis of white adipose tissue depots (Figure 6C) at the end
of this experiment again showed decreases in weight following
PSN632408 or sibutramine treatment for all sites examined.
This reached statistical significance for epididymal and mesen-
teric depots and also for the total of the white adipose tissue
depots examined in the PSN632408-treated rats and formesen-
teric and total white adipose tissue depots in the sibutramine-
treated rats. The intrascapular brown adipose tissue depots
were not affected by PSN632408 or sibutramine treatment
(data not shown).
Plasma leptin concentrations at the end of the study
(Figure 6D) showed an identical trend to fat depot mass, withCELL METABOLISM : MARCH 2006
A GPCR for OEA and synthetic hypophagic agentsFigure 6. Subchronic dosing of normal rats on high-fat diet with PSN632408 and sibutramine
A) Cumulative food intake (kJ/kg body weight) and (B) body weight (percentage of day 0 value) for groups of 10 rats dosed daily p.o. (commencing on day 0) with vehicle
(open squares; mean body weight 3056 7 g on day 0), 100 mg/kg PSN632408 (filled circles; mean body weight 3066 5 g on day 0), or 5 mg/kg sibutramine hydrochloride
hydrate (filled triangles; mean body weight 3036 5 g on day 0). A further group of 4 rats on standard chow diet was dosed daily with vehicle (open circles; mean body weight
2756 5 g on day 0). Results are presented as means + SEM. Significant differences from the vehicle-treated HFD controls (p < 0.05; ANOVA followed by Fisher’s post-hoc
test) are denoted by * (PSN632408), + (sibutramine), and # (chow-fed controls).
C)Weights of fat pad masses removed on day 24 (24 hr after final dose) from rats treated with vehicle, PSN632408, sibutramine, or chow-fed controls, respectively. ING =
inguinal, EP = epididymal, MES =mesenteric, RP = retroperitoneal, WAT = total of ING, EP, MES, and RP. Values expressed in g (mean + SEM). Significant differences from
the vehicle-treated HFD controls are denoted by * (p < 0.05; ANOVA factorial, Fisher’s post-hoc test).
D) Plasma leptin levels at day 24 (24 hr after final dose) from rats treated with vehicle, PSN632408, sibutramine, or chow-fed controls. Values expressed in ng/ml (mean +
SEM). Significant differences from the vehicle-treated HFD controls are denoted by * (p < 0.05; ANOVA, Bonferroni’s modified T-test).PSN632408 and sibutramine treatment ameliorating the rises in
leptin concentration measured in the HFD-fed animals com-
pared to lean chow controls. Furthermore, measurements of
plasma glucose and insulin levels at the end of the study showed
a trend, albeit not statistically significant, toward improvement in
insulin sensitivity in the sibutramine- and PSN632408-treated
animals compared to HFD vehicle controls (plasma insulin:
HFD controls = 279 6 50 pM; PSN632408-treated = 210 6
22 pM; sibutramine-treated = 256 6 64 pM; lean controls =
142 6 48 pM; plasma glucose: HFD controls = 5.39 6 0.89
mM; PSN632408-treated = 3.61 6 0.27 mM; sibutramine-
treated = 3.78 6 0.32 mM; lean controls = 3.86 6 0.69 mM).
In conclusion, we have discovered that the naturally occurring
feeding regulator OEA is an agonist at theGPR119 receptor, and
that a selective, small-molecule agonist at this receptor acts to
suppress feeding and reduce body weight gain and adiposityCELL METABOLISM : MARCH 2006in rat models following oral dosing. Details of the mechanisms
by which these effects are produced remain to be elucidated,
but it is clear that this receptor system is a novel putative avenue
for controlling caloric intake and body weight and hence has
great potential value for discovering pharmaceuticals to allevi-
ate the burdens of obesity and related metabolic disorders.
Experimental procedures
Cloning of human and mouse OSGPR116 receptors
The gene for the mouse OSGPR116 (GPR119) receptor was PCR amplified
from mouse genomic DNA using the following primers: 50TATATCGTCTC
TCATGGAGTCATCCTTC30 (forward) and 50TATATTCTAGATTAGCCATCGA
GCTCCGG30 (reverse). The amplified product was digested with restriction
enzymes BsmBI and XbaI, creating an NcoI-compatible overhang at the 50
end of the product, and inserted into the yeast expression vector Cp4258
(Miret et al., 2002) at the NcoI/XbaI restriction sites. In the resulting construct,173
A R T I C L Eexpression of OSGPR116 is under the control of the PGK promoter while the
N terminus of the receptor gene is fused to an 89 amino acid Mfa1-leader se-
quence, allowing its transport to the cell membrane. A similar protocol was
followed for cloning the human OSGPR116 gene into the yeast expression
vector. PCR amplification of the human gene was accomplished using hu-
man genomic DNA and the following primers: 50CTCTTCGGTCTCTC
ATGGAATCATCTTTCTCATTTGGAGTGATC30 (forward) and 50CTCTTCTC
TAGACTTAGCCATCAAACTCTGAGCTGGAGATAGTG30 (reverse). Ampli-
fied product was digested with the restriction enzymes BsaI and XbaI, creat-
ing an NcoI-compatible overhang at the 50 end of the product, and inserted
into the yeast expression vector Cp4258 at the NcoI/XbaI restriction sites.
The sequences of the amplified human and mouse OSGPR116 coding re-
gions were later confirmed to be identical to those given for GPR119 (Fre-
driksson et al., 2003) and SNORF25 (Bonini et al., 2002). For the sake of clar-
ity, the receptors are referred to as GPR119 throughout this paper.
Yeast fluorescent reporter assay
Yeast cell-based reporter assays have previously been described in the liter-
ature (King et al., 1990; Campbell et al., 1999; Miret et al., 2002). Saccharo-
myces cerevisiae cells have been engineered such that the endogenous
yeast G-a (GPA1) has been replaced with a G protein chimera. Additionally,
the endogenous yeast GPCR, Ste3, has been deleted to allow for the heter-
ologous expression of a mammalian GPCR of choice. In the yeast, elements
of the pheromone signaling transduction pathway drive the expression of
Fus1. By placing the b-galactosidase (LacZ) gene under the control of the
Fus1 promoter (Fus1p), receptor activation can bymonitored by a fluorescent
read-out. Yeast cells were cotransformed with either a human or mouse
GPR119 expression plasmid (as described above) carrying a LEU auxotro-
phic marker, and two Fus1p-LacZ reporter plasmids, with auxotrophic
markers for URA and TRP. Transformants were grown on selective plates
lacking leucine, uracil, and tryptophan. For the fluorimetric functional assay,
recombinant yeast strains were grown to mid-log phase in synthetic defined
mediumwithout leucine, uracil, and tryptophan, pH 6.8 (Qbiogene Inc, Carls-
bad, California) andmixedwith test compounds in opaque 96-well plates. Di-
methyl sulfoxide (DMSO) was present at 1% final concentration. After 4 hr in-
cubation at 30ºC, fluorescein di (b-D-galactopyranoside) substrate at a final
concentration of 80 mMand Triton X100 at a final concentration of 0.4%were
added to each well. Incubation was continued for 60 min at 30ºC and sodium
carbonate then added to a final concentration of 140 mM to terminate the re-
action and enhance the fluorescent signal. The plates were read in a fluorim-
eter at 485/535 nm.
Mammalian cell line expressing GPR119
A stable cell line that expresses human GPR119 when induced with tetracy-
cline (HEK-OSGPR116 cell line) was created using the Flp-In T-REx system
(Invitrogen Ltd.) according to the manufacturer’s protocol. Flp-In T-REx-293
cells were transfected with the plasmid pcDNA5/FRT/TO into which the
GPR119 open reading frame had been inserted, and a population of stable
transfectants was selected using hygromycin. A control cell line was derived
in a similar manner using the plasmid pcDNA5/FRT/TO/CAT which contains
the chloramphenicol acetyl transferase gene instead of GPR119. Cells were
cultured in DMEM (Invitrogen #31966-021) supplemented with 10% fetal bo-
vine serum, hygromycin (50 mg/ml) and blasticidin (15 mg/ml). Expression of
the GPR119 gene was demonstrated by quantitative RT-PCR using the
ABI Prism 7000 Sequence Detection System and primers with the following
sequences:
50AAAGATGGAACATGAGGAGCC30 (forward), 50GAGCTTTGAAGTCGC
TGGGAG30 (reverse) and 50FAM-TGGCTGGAGGTTATCGATCCCCACG-
TAMRA30 (TaqMan probe).
Intracellular cyclic AMP determination
HEK-OSGPR116 cell monolayers were pretreated overnight with 10–20 ng/
ml tetracycline, these conditions having been found to induce GPR119 ex-
pression at an optimal level for subsequent experiments. Treated mono-
layers were then incubated for 30 min at 37ºC with test compounds in stim-
ulation buffer plus 1% DMSO. Cells were lysed and cyclic AMP (cAMP)
content determined using the Perkin Elmer AlphaScreen (Amplified Lumines-
cent Proximity Homogeneous Assay) cAMP kit. Buffers and assay conditions
were as described in the manufacturer’s protocol.174Acute feeding experiments
Acute feeding experiments were carried out using singly housed male
Sprague-Dawley rats (Charles River Laboratories). Rats were maintained
on a reverse-phase light-dark cycle and had free access to standard pow-
dered rat diet. Prior to the start of the experiment, rats were allocated to
weight-matched treatment groups. Compounds were administered during
the 30 min prior to the start of the dark phase, either by intraperitoneal injec-
tion using 5% propylene glycol/5% Tween 80/90% saline as vehicle or by
oral gavage using 25% Gelucire 44/14:75% water as vehicle. Food intake
was monitored either by weighing feeding jars at 1, 2, 4, 6, and 24 hr after
drug administration (Figures 4A andS2) or by an automated system providing
online measurements of food intake and locomotor activity every fifth minute
(Tang-Christensen et al., 2004) (Figures 4B, 4C, and S4).
Subchronic feeding experiments
Male DIO Levin rats (bred at Rheoscience) or normal male Sprague-Dawley
rats (Charles River Laboratories) were housed singly under a 12 hr/12 hr
light/dark cycle in temperature and humidity controlled rooms and offered
an energy-dense high-fat diet (kcal 32% fat; 51% carbohydrate; 17% pro-
tein, #12266B; Research Diets, New Jersey) and water ad libitum. Weight-
matched groups of 8–10 animals received single daily oral gavage (30 min
before lights out) of test compound or vehicle control (25% Gelucire 44/
14:75% water). Animals were habituated to the dosing paradigm by mock
gavage for 3 days prior to the start of dosing. Sibutramine was dosed as
5 mg/kg sibutramine hydrochloride hydrate. Body weight and food intake
were measured once daily. At 24 hr after the final dose terminal blood sam-
ples were taken for plasma glucose (GO assay kit, Sigma), insulin (Rat insulin
ELISA kit, Mercodia, Sweden), and leptin (Rat leptin ELISA kit, Linco Res.)
measurements. Adipose tissue depots were removed from the animals and
weighed.
Supplemental data
Supplemental data include four figures and can be found with this article on-
line at http://www.cellmetabolism.org/content/full/3/3/167/DC1/.
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